Innate Immunotherapeutics Company
Innate Immunotherapeutics has a Phase 2B drug candidate to treat secondary progressive multiple sclerosis (SPMS ).
Technology:
Others
Industry:
PharmTech
Headquarters:
Sydney, New South Wales, Australia
Founded Date:
2000
Employees Number:
1-10
Funding Status:
IPO
Register and Claim Ownership